Skip to search formSkip to main contentSkip to account menu

Ribonucleotide Reductase Inhibitor

Any substance that inhibits ribonucleotide reductase, an enzyme that catalyzes the conversion of ribonucleoside diphosphates to deoxyribonucleotide… 
National Institutes of Health

Related topics

Related topics

1 relation
Ribonucleotide Reductase Inhibitors [MoA]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer
Head and neck squamous cell carcinomas (HNSCCs) are the sixth most common malignant neoplasm and more than 50% of patients… 
2008
2008
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia
SummaryPurpose: This Phase I dose escalation study was based on the hypothesis that the addition of 3-aminopyridine-2… 
Highly Cited
2004
Highly Cited
2004
Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
PURPOSE 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP; Triapine; Vion Pharmaceuticals Inc, New Haven, CT) is a potent… 
Highly Cited
2003
Highly Cited
2003
Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
PURPOSE A Phase I study in patients with advanced cancer was conducted to determine the safety, pharmacokinetics, and maximum… 
Highly Cited
2002
Highly Cited
2002
Didox (A Novel Ribonucleotide Reductase Inhibitor) Overcomes bcl-2 Mediated Radiation Resistance in Prostate Cancer Cell Line PC-3
In this study, we investigated the influence of bcl-2 overexpression on the radiosensitizing potential of Didox (DX; 3,4… 
Highly Cited
2001
Highly Cited
2001
The ribonucleotide reductase inhibitor Sml1 is a new target of the Mec1/Rad53 kinase cascade during growth and in response to DNA damage
The evolutionarily conserved protein kinases Mec1 and Rad53 are required for checkpoint response and growth. Here we show that… 
1998
1998
Antiviral Activity of a Selective Ribonucleotide Reductase Inhibitor against Acyclovir-Resistant Herpes Simplex Virus Type 1 In Vivo
ABSTRACT The present study reports the activity of BILD 1633 SE against acyclovir (ACV)-resistant herpes simplex virus (HSV… 
Highly Cited
1997
Highly Cited
1997
Rnr4p, a novel ribonucleotide reductase small-subunit protein
Ribonucleotide reductases catalyze the formation of deoxyribonucleotides by the reduction of the corresponding ribonucleotides… 
Highly Cited
1990
Highly Cited
1990
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
The new deoxycytidine analogue 2',2'-difluorodeoxycytidine (dFdC) is a specific inhibitor of DNA synthesis that has marked… 
1988
1988
A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor.
A phase 1 study of a new ribonucleotide reductase inhibitor, didox, was performed by administration of escalating doses of the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)